Jack Bailey

President, US Pharmaceuticals

Jack Bailey

Jack Bailey oversees GSK’s pharmaceuticals and vaccines businesses in the US and Puerto Rico.  In this role, Jack draws upon 25 years of industry experience and a successful track record of leading organizations through change, delivering strong business performance and maintaining a focus on patient access and affordability. 

Jack joined GSK in 2009 as a senior vice president.  His in-depth understanding of US market dynamics and the evolution of a value-based healthcare system has guided GSK through a period of intense change in the US healthcare system. A firm believer in the connections between public policy, funding and delivery of healthcare, Jack successfully brought together GSK’s managed markets, public policy, and government affairs teams to tackle the large and multi-faceted challenges facing the pharmaceutical sector today.  He also led GSK’s U.S. Vaccines business and Puerto Rico operations. 

Prior to joining GSK, Jack had a successful 18-year career with Eli Lilly, where he served in a variety of commercial leadership roles including senior vice president of the account-based markets division, general manager for Eli Lilly South Africa, and area director for the sub-Saharan region. Jack’s experience in Africa, where he saw first-hand the personal consequences of the AIDS crisis, has shaped much of how he approaches business today, taking a keen interest in cutting edge science, as well as working to ensure great innovation is accessible to those who need it. 

Jack holds a Master of Business Administration from the University of North Carolina, Kenan Flagler School of Business. He lives in North Carolina with his wife and two children. He is actively involved in the community and the healthcare sector in the state, and has served on the boards of the North Carolina Biotechnology Center, the North Carolina Healthcare Quality Alliance, and the North Carolina Chamber of Commerce. Jack serves on the board of the Pharmaceutical Research and Manufacturers of America (PhRMA) and is currently a member of the Health Policy and Management Executive Council at the Harvard T.H. Chan School of Public Health.